Novo Nordisk A/S (TSX:NOVO)

Novo Nordisk Revenue

Novo Nordisk had revenue of 78.49B DKK in the quarter ending June 30, 2026, with 2.12% growth. This brings the company's total for the last twelve months to 329.43B, up 5.61% year-over-year. In the year 2025, Novo Nordisk had annual revenue of 309.06B with 6.43% growth.

• Revenue (ttm): 329.43B DKK
• Revenue Growth: +5.61%
• P/S Ratio: 3.38
• Revenue / Employee: 4.94M DKK
• Employees: 66,700
• Market Cap: 241.60B CAD

Revenue Chart

Chart

Chart

* This company reports financials in DKK.

Revenue by Segment

By Segment

Chart

• Ozempic Injectable 127.09B 41.1%
• Wegovy Injectable 79.11B 25.6%
• Ozempic Pill / Rybelsus 22.09B 7.1%
• Long-Acting Insulin 18.76B 6.1%
• Fast-Acting Insulin 18.58B 6.0%
• Rare Blood Disorders 11.96B 3.9%
• Premix Insulin 10.32B 3.3%
• Other 21.17B 6.8%

By Geography

Chart

• US 173.17B 56.0%
• EUCAN 66.09B 21.4%
• Emerging Markets 30.44B 9.8%
• APAC 20.71B 6.7%
• China 18.66B 6.0%

Fiscal year ended Dec 31, 2025 See the full Novo Nordisk breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	309.06B	18.66B	6.43%
Dec 31, 2024	290.40B	58.14B	25.03%
Dec 31, 2023	232.26B	55.31B	31.26%
Dec 31, 2022	176.95B	36.15B	25.68%
Dec 31, 2021	140.80B	13.85B	10.91%
Dec 31, 2020	126.95B	4.93B	4.04%
Dec 31, 2019	122.02B	10.19B	9.11%
Dec 31, 2018	111.83B	135.00M	0.12%
Dec 31, 2017	111.70B	-84.00M	-0.08%
Dec 31, 2016	111.78B	3.85B	3.57%
Dec 31, 2015	107.93B	19.12B	21.53%
Dec 31, 2014	88.81B	5.23B	6.26%
Dec 31, 2013	83.57B	5.55B	7.11%
Dec 31, 2012	78.03B	11.68B	17.60%
Dec 31, 2011	66.35B	5.57B	9.16%
Dec 31, 2010	60.78B	9.70B	18.99%
Dec 31, 2009	51.08B	5.53B	12.13%
Dec 31, 2008	45.55B	3.72B	8.90%
Dec 31, 2007	41.83B	-	-

Data Source: Fiscal.ai Last updated: Jun 30, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 26, 2026

Data Sources Report a data error